Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 30/100

SKYE LAWSUIT ALERT: The Gross Law Firm Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Key Takeaway: The Gross Law Firm has issued a notice regarding a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) for allegedly misleading shareholders about its lead product candidate, nimacimab. The lawsuit claims that the effectiveness of nimacimab was overstated and that the company failed to disclose significant information to investors. Shareholders who purchased SKYE shares during the specified class period from November 4, 2024, to October 3, 2025, are encouraged to register for participation in the class action by the deadline of January 16, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges that Skye Bioscience misled investors regarding the effectiveness of its lead product candidate, nimacimab.
  • Claims suggest that the company's public statements were materially false and misleading.
  • The overstatement of clinical, regulatory, and commercial prospects of nimacimab raises serious concerns for investors.

Full Press Release Details

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).
Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 4, 2024 to October 3, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: January 16, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/?id=180541&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SKYE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is January 16, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Skye Bioscience shares?

The class period for Skye Bioscience shares is from November 4, 2024, to October 3, 2025.

What allegations are made against Skye Bioscience?

Allegations include misleading statements regarding the effectiveness of nimacimab and overstated clinical prospects.

What is the deadline to seek lead plaintiff status?

The deadline to seek lead plaintiff status is January 16, 2026.

Is there a cost to participate in this class action?

There is no cost or obligation to participate in this class action.

How can shareholders register for the class action?

Shareholders can register by submitting their information at the provided link.

Last updated: Dec 17, 2025